Literature DB >> 11113626

Microsomal fatty aldehyde dehydrogenase catalyzes the oxidation of aliphatic aldehyde derived from ether glycerolipid catabolism: implications for Sjögren-Larsson syndrome.

W B Rizzo1, E Heinz, M Simon, D A Craft.   

Abstract

The enzyme that catalyzes the oxidation of fatty aldehyde derived from ether glycerolipid catabolism has not been identified. To determine whether microsomal fatty aldehyde dehydrogenase (FALDH) is responsible, we investigated the metabolism of 1-O-[9, 10-(3)H-octadecyl]-glycerol ([(3)H]OG) in FALDH-deficient cultured cells from patients with Sjögren-Larsson syndrome (SLS) and in mutant Chinese hamster ovary (CHO) cells. Intact fibroblasts from SLS patients incubated with [(3)H]OG showed a selective deficiency (38+/-7% of normal) in the incorporation of radioactivity into fatty acid, but no decrease in incorporation of radioactivity into fatty alcohol, total lipids and phosphatidylethanolamine (PE). Consistent with fatty aldehyde accumulation, incorporation of radioactivity into N-alkyl-phosphatidylethanolamine, which is derived from Schiff base formation of free aldehyde with PE, was 4-fold higher in SLS fibroblasts compared to normal controls. Similar results were seen with SLS keratinocytes, whereas FALDH-deficient CHO cells showed a more profound reduction in radioactive fatty acid to 12+/-2% of normal. These results implicate FALDH in the oxidation of ether-derived fatty aldehyde in human and rodent cells. Metabolism of ether glycerolipids is a previously unrecognized source of fatty aldehyde that may contribute to the pathogenesis of SLS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11113626     DOI: 10.1016/s0925-4439(00)00077-6

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  19 in total

1.  Disruption of the Sjögren-Larsson Syndrome Gene Aldh3a2 in Mice Increases Keratinocyte Growth and Retards Skin Barrier Recovery.

Authors:  Tatsuro Naganuma; Shuyu Takagi; Tsukasa Kanetake; Takuya Kitamura; Satoko Hattori; Tsuyoshi Miyakawa; Takayuki Sassa; Akio Kihara
Journal:  J Biol Chem       Date:  2016-04-06       Impact factor: 5.157

Review 2.  Sjögren-Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency.

Authors:  William B Rizzo
Journal:  Mol Genet Metab       Date:  2006-09-22       Impact factor: 4.797

Review 3.  Plasmalogens and fatty alcohols in rhizomelic chondrodysplasia punctata and Sjögren-Larsson syndrome.

Authors:  Ana R Malheiro; Tiago Ferreira da Silva; Pedro Brites
Journal:  J Inherit Metab Dis       Date:  2014-11-29       Impact factor: 4.982

4.  Chlorinated lipid species in activated human neutrophils: lipid metabolites of 2-chlorohexadecanal.

Authors:  Dhanalakshmi S Anbukumar; Laurie P Shornick; Carolyn J Albert; Melissa M Steward; Raphael A Zoeller; William L Neumann; David A Ford
Journal:  J Lipid Res       Date:  2009-12-17       Impact factor: 5.922

Review 5.  Aldehyde dehydrogenases: from eye crystallins to metabolic disease and cancer stem cells.

Authors:  Vasilis Vasiliou; David C Thompson; Clay Smith; Mayumi Fujita; Ying Chen
Journal:  Chem Biol Interact       Date:  2012-11-16       Impact factor: 5.192

6.  MR imaging and proton MR spectroscopic studies in Sjögren-Larsson syndrome: characterization of the leukoencephalopathy.

Authors:  Michèl A A P Willemsen; Marinette Van Der Graaf; Marjo S Van Der Knaap; Arend Heerschap; Peter H M F Van Domburg; Fons J M Gabreëls; Jan J Rotteveel
Journal:  AJNR Am J Neuroradiol       Date:  2004-04       Impact factor: 3.825

Review 7.  Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily.

Authors:  Satori A Marchitti; Chad Brocker; Dimitrios Stagos; Vasilis Vasiliou
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-06       Impact factor: 4.481

Review 8.  S1P and plasmalogen derived fatty aldehydes in cellular signaling and functions.

Authors:  David L Ebenezer; Panfeng Fu; Ramaswamy Ramchandran; Alison W Ha; Vijay Putherickal; Tara Sudhadevi; Anantha Harijith; Fabian Schumacher; Burkhard Kleuser; Viswanathan Natarajan
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2020-03-12       Impact factor: 4.698

9.  Genetics and prospective therapeutic targets for Sjögren-Larsson Syndrome.

Authors:  William B Rizzo
Journal:  Expert Opin Orphan Drugs       Date:  2016-03-10       Impact factor: 0.694

10.  A Pex7 hypomorphic mouse model for plasmalogen deficiency affecting the lens and skeleton.

Authors:  Nancy Braverman; Rui Zhang; Li Chen; Graeme Nimmo; Sarah Scheper; Tammy Tran; Rupsa Chaudhury; Ann Moser; Steven Steinberg
Journal:  Mol Genet Metab       Date:  2009-12-11       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.